The Importance of Local Therapies in Lower Risk Metastatic Disease

The P53 wild type PMMR patients are unique and we have a number of studies for them in the front line, in the adjuvant setting. That population has been studied in a trial called B21, which has more than a thousand patients and it's done. And then the third point, this P53 man, I liked what you said, then in the P53 mutated, there is an opportunity for checkpoint,.